Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
-
Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET
-
管理层将于美国东部时间2024年5月9日星期四上午 8:30 主持电话会议
FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, May 9, 2024, to report its first quarter 2024 financial results and provide an update on business progress.
新泽西州弗洛勒姆公园，2024年4月29日（GLOBE NEWSWIRE）——专注于开发和商业化胃肠道疾病新疗法的生物制药公司Phathom Pharmicals, Inc.（纳斯达克股票代码：PHAT）今天宣布，将在美国东部时间2024年5月9日星期四上午8点30分举办网络直播，报告其2024年第一季度财务业绩并提供最新业务进展。
A live webcast and additional information about the presentation can be accessed on the News & Events section of the Phathom website at A recording will be available for 90 days following the conclusion of the meeting.
可以在Phathom网站的 “新闻与活动” 部分访问网络直播和有关演示的其他信息。会议结束后的90天内将提供录像。
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA (vonoprazan) tablets for the treatment of Erosive GERD and relief of related heartburn in adults, in addition to VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the Company's website at and follow the Company on LinkedIn and X.
关于 Phathom 制药公司
Phathom Pharmaceuticals是一家生物制药公司，专注于胃肠道疾病新疗法的开发和商业化。Phathom已获得vonoprazan的独家使用许可，vonoprazan是一种同类首创的钾竞争性酸阻滞剂（PCAB），目前在美国以VOQUEZNA的名义销售 （vonoprazan）片剂除VOQUEZNA外，还用于治疗侵蚀性胃食管反流病和缓解成人相关胃灼热 三重公园 （沃诺普拉赞片剂、阿莫西林胶囊、克拉霉素片剂）和 VOQUEZNA 双包 （沃诺普赞片剂，阿莫西林胶囊）用于治疗 幽门螺杆菌 成人感染。有关 Phathom 的更多信息，请访问公司网站，并在 LinkedIn 和 X 上关注该公司。
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
媒体联系人
尼克·贝内代托
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
投资者联系人
埃里克·西奥里利
1-877-742-8466
ir@phathompharma.com
2024 Phathom Pharmaceuticals. All rights reserved.
2024 Phathom 制药。版权所有。